sever
acut
respiratori
syndrom
sar
atyp
pneumonia
diseas
caus
human
coronaviru
cov
new
global
public
health
problem
major
outbreak
sar
infect
occur
china
hong
kong
singapor
vietnam
taiwan
canada
countri
report
suspect
probabl
case
sarscov
mutant
human
cov
may
acquir
new
virul
factor
although
tempor
progress
clinic
radiolog
virolog
chang
sar
extens
studi
sever
treatment
propos
yet
effect
strategi
prevent
sar
pathogen
mechan
still
unresolv
sar
patholog
onset
respiratori
symptom
suggest
result
multipl
factor
respiratori
epithelium
disrupt
includ
viral
cytotox
host
factor
genet
variat
sarscov
viral
load
seem
respons
sever
sar
addit
abnorm
immun
respons
sarscov
infect
unbal
immun
cell
product
dysregul
cytokin
chemokin
may
also
underli
pathogenesi
diseas
immunemedi
mechan
involv
sar
pathogenesi
howev
fulli
understood
onset
autoimmun
relat
viral
infect
influenza
viral
infectioninduc
autoimmun
diseas
call
goodpastur
syndrom
show
exist
autoantibodi
autoab
alveolar
glomerular
basement
membran
report
regard
sarscovinduc
autoab
product
nevertheless
murin
cov
infect
induc
autoreact
cell
b
cell
polyclon
activ
autoab
product
immunemedi
patholog
relat
sarscov
infect
thu
merit
examin
present
studi
gener
pathogen
role
autoab
sar
patient
investig
sar
patient
sera
collect
centr
diseas
control
depart
health
taiwan
cdctaiwan
march
june
diagnosi
sar
base
clinic
criteria
establish
patient
sarscov
confirm
laboratori
method
includ
viral
antigen
detect
rtpcr
serolog
method
epidemiolog
characterist
age
gender
clinic
inform
symptom
underli
diseas
outcom
includ
death
hospit
lengthofstay
well
laboratori
find
obtain
cdctaiwan
unpublish
observ
sar
patient
sera
collect
earli
patient
day
fever
onset
late
patient
day
stage
includ
studi
sera
patient
collect
two
three
time
late
stage
serum
sampl
patient
test
eight
serum
sampl
patient
diagnos
pneumonia
nonsar
aetiolog
obtain
dr
r
hsiue
intern
medicin
nation
cheng
kung
univers
hospit
tainan
serum
sampl
healthi
individu
use
control
human
lung
adenocarcinoma
cell
line
hepatoma
cell
line
lung
fibroblast
grown
dmem
human
lung
epitheli
cell
line
hl
grown
mem
supplement
heatinactiv
fetal
calf
serum
fc
mm
lglutam
ngml
gentamycin
human
microvascular
endotheli
cell
pass
cultur
plate
contain
endotheli
cell
growth
medium
clonet
walkersvil
md
usa
compos
fc
hydrocortison
ngml
epiderm
growth
factor
antibiot
cell
incub
incub
humidifi
atmospher
microscop
observ
monolay
cell
cultur
steril
glass
slide
experi
flow
cytometr
analysi
cell
suspens
prepar
trypsin
cell
cultur
cell
wash
briefli
phosphatebuff
salin
pb
fix
paraformaldehyd
pb
room
temperatur
min
wash
pb
patient
serum
sampl
mous
antisar
spike
protein
anti
spike
protein
domain
spike
protein
domain
ab
incub
cell
h
wash
three
time
pb
cell
incub
fitcconjug
mous
antihuman
igg
igm
iga
goat
antimous
igg
jackson
immunoresearch
laboratori
inc
west
grove
pa
usa
respect
h
wash
pb
cell
bind
activ
sera
ab
analys
fluoresc
microscopi
flow
cytometri
facscalibur
bd
bioscienc
san
jose
ca
usa
excit
set
nm
cytotox
assay
test
sera
pretreat
min
complement
inactiv
monolay
cell
cultur
plate
experi
cell
wash
briefli
steril
serumfre
cultur
medium
treat
serum
sampl
h
supernat
collect
cytotox
determin
use
lactat
dehydrogenas
ldh
releas
kit
situ
cell
cytotox
kit
roch
molecular
biochem
indianapoli
usa
accord
manufactur
instruct
percentag
cytotox
calcul
construct
express
vector
cdna
sar
code
region
amplifi
pcr
carri
use
kind
gift
dr
c
j
huang
academia
sinica
taipei
taiwan
templat
forward
primer
contain
ecori
restrict
site
ital
revers
primer
contain
stop
codon
underlin
xbai
restrict
site
ital
amplifi
dna
fragment
clone
ecori
xbai
site
vector
new
england
biolab
beverli
usa
maltos
bind
protein
mbp
gene
produc
ligat
transform
perform
use
electropor
biorad
laboratori
inc
hercul
ca
usa
construct
verifi
dna
sequenc
perform
use
kit
abipr
dye
termin
cycl
sequenc
kit
perkinelm
appli
biosystem
foster
citi
ca
usa
express
purif
sar
fusion
protein
e
coli
bear
construct
express
grown
luriabertani
medium
ampicillin
cell
cultur
reach
od
nm
protein
express
induc
addit
mm
iptg
h
verifi
express
cell
collect
centrifug
disrupt
directli
sdspage
sampl
load
buffer
largescal
purif
cell
harvest
centrifug
suspend
bind
buffer
mm
trishcl
ph
contain
mm
nacl
mm
edta
cell
lyse
sonic
ice
cell
lysat
clarifi
centrifug
g
min
clear
supernat
load
onto
column
contain
amylos
resin
new
england
biolab
equilibr
bind
buffer
column
wash
three
volum
bind
buffer
fusion
protein
elut
buffer
contain
mm
maltos
final
purifi
fusion
protein
concentr
use
filter
unit
centricon
centrifug
filter
unit
millipor
corp
bedford
usa
protein
concentr
variou
fraction
determin
bradford
spectrophotometr
method
biorad
duplic
averag
valu
calcul
publicli
avail
human
cov
genom
sequenc
nation
center
biotechnolog
inform
usa
use
insilico
predict
algorithm
immunogen
secondstructur
predict
protein
topolog
analysi
hydrophob
appli
design
test
peptid
protein
sequenc
spike
protein
obtain
genbank
access
number
immunogen
viral
peptid
calcul
base
algorithm
develop
kolaskar
tongaonkar
insilico
secondari
structur
analys
spike
protein
perform
base
two
algorithm
phd
predat
protein
topolog
predict
base
algorithm
develop
tmhmm
hydrophob
moment
peptid
calcul
base
algorithm
hmoment
similar
search
perform
spike
protein
human
genom
databas
use
ncbi
blastp
program
blastp
analysi
default
databas
collect
nonredund
genbank
cdna
sequenc
translat
pdb
swissprot
pir
prf
entri
use
speci
restrict
human
final
expert
curat
appli
refin
peptid
design
multipl
antigen
peptid
synthes
cytomol
corp
mountain
view
ca
usa
sever
synthet
peptid
use
studi
residu
nasyhtvsllrstsqkc
residu
neegnlllqygsfctqc
residu
nglgklqdvvnqngec
residu
nalntlvkqlssnc
extra
amino
acid
residu
ad
either
n
cterminu
indic
ital
letter
increas
hydrophob
preabsorpt
patient
sera
sarscov
four
synthet
peptid
use
done
use
solidphas
captur
techniqu
individu
peptideco
plate
elisa
plate
coat
without
peptid
block
bovin
serum
albumin
bsa
coat
buffer
mm
sodium
carbon
mm
sodium
bicarbon
ph
test
serum
sampl
dilut
ad
plate
overnight
absorpt
supernat
collect
well
incub
cell
bind
assay
describ
detect
ab
titr
sera
elisa
plate
wash
pbstween
pbst
five
time
whereaft
hrpconjug
antihuman
igg
ad
mgml
jackson
immunoresearch
laboratori
dilut
wash
pbst
abt
peroxidas
substrat
triniti
biotech
plc
bray
co
wicklow
ireland
ad
absorb
measur
use
micropl
reader
emax
molecular
devic
corp
sunnyval
ca
usa
nm
cell
cellswel
plate
glass
chamber
slide
nalg
nunc
intern
napervil
il
usa
monolay
confluent
cell
treat
hyperimmun
sera
serumfre
cultur
medium
h
incub
cell
wash
medium
incub
h
isol
healthi
human
peripher
blood
mononuclear
cell
pbmc
cellswel
total
volum
end
incub
period
nonadher
cell
remov
wash
twice
bsa
pb
adher
cell
stain
liu
stain
tonyar
biotech
taipei
taiwan
view
light
microscopi
adher
cell
count
three
consecut
microscop
field
comparison
variou
treatment
perform
use
student
ttest
sigmaplot
version
window
cytel
softwar
corp
cambridg
md
usa
nonpair
student
ttest
use
data
analys
tabl
fig
pair
student
ttest
use
data
analys
fig
valu
consid
statist
signific
p
pulmonari
defect
clinic
featur
sarscov
infect
attempt
investig
role
play
sar
patient
sera
bind
activ
patient
sera
human
epitheli
cell
determin
fluoresc
microscop
observ
show
ab
present
sar
patient
sera
react
uninfect
epitheli
cell
sera
healthi
control
fig
flow
cytometr
analysi
averag
igg
level
significantli
higher
late
stage
day
fever
onset
compar
earli
stage
day
fever
onset
healthi
control
fig
tabl
although
patient
sera
igm
iga
late
stage
exhibit
high
cell
bind
activ
fig
averag
level
significantli
differ
earli
stage
healthi
control
tabl
epitheli
cell
bind
activ
ab
significantli
elev
nonsarspneumonia
patient
sera
fig
tabl
autoab
level
start
increas
day
reach
highest
level
around
day
declin
gradual
thereaft
sampl
patient
fig
tabl
consequ
serum
bind
cell
next
assess
cell
cytotox
induc
patient
sera
measur
use
ldh
activ
assay
sera
late
phase
use
result
show
sar
patient
sera
induc
cytotox
averag
od
n
compar
sera
healthi
control
averag
od
n
nonsarspneumonia
patient
sera
averag
od
n
fig
percentag
cytotox
show
pattern
similar
od
valu
fig
preabsorpt
igg
fraction
protein
g
result
reduct
cytotox
level
similar
healthi
control
indic
cytotox
effect
caus
igg
present
sar
patient
sera
data
shown
complement
inactiv
patient
sera
perform
experi
therefor
epitheli
cell
injuri
must
mediat
patient
igg
via
complementindepend
pathway
howev
possibl
complementmedi
cytotox
may
play
role
exclud
analysi
show
statist
signific
correl
level
igg
igm
iga
magnitud
epitheli
cell
cytotox
fig
addit
cell
examin
whether
autoab
present
sar
patient
sera
also
react
cell
type
sar
patient
sera
detect
bound
human
endotheli
cell
line
human
hepatoma
cell
line
lesser
extent
lung
fibroblast
cell
demonstr
flow
cytometr
analysi
data
shown
sever
synthet
peptid
design
viral
epitop
share
sequenc
homolog
human
protein
fig
panel
screen
proceed
two
spikeprotein
peptid
design
appear
bound
sar
patient
sera
fig
two
peptid
locat
domain
spike
protein
bind
patient
sera
also
confirm
fig
valid
epitop
share
viral
selfantigen
sar
patient
sera
preabsorb
variou
peptid
bind
activ
determin
result
indic
cell
bind
activ
patient
sera
reduc
preabsorpt
fig
peptid
bound
patient
sera
fig
accordingli
caus
inhibit
fig
exist
crossreact
epitop
sarscov
share
homolog
host
cell
protein
therefor
demonstr
character
epitheli
cell
crossreact
anti
ab
mous
ab
direct
test
bind
activ
cell
use
flow
cytometri
analysi
higher
level
cell
bind
abil
anti
ab
fig
bind
abil
anti
ab
surfac
epitheli
cell
also
confirm
confoc
microscopi
fig
studi
use
human
lung
epitheli
cell
line
hl
bind
activ
indic
anti
ab
could
also
bind
lung
epitheli
cell
fig
explor
effect
ab
bind
epitheli
cell
adher
pbmc
cell
investig
cytokin
storm
increas
product
previous
shown
adhes
pbmc
cell
presenc
absenc
ab
also
assess
result
show
higher
level
pbmc
adher
could
observ
cell
treat
h
compar
untreat
group
fig
interestingli
promot
adhes
pbmc
cell
greatli
enhanc
combin
treatment
fig
therefor
addit
cell
injuri
crosslink
ab
also
upregul
immun
cell
adhes
epitheli
cell
studi
use
immunostain
indic
monocyt
pbmc
major
cell
popul
preferenti
bind
cell
data
shown
accord
find
macrophag
promin
leucocyt
alveoli
sar
patient
competit
bind
assay
synthet
peptid
protein
inhibit
adhes
pbmc
cell
fig
novel
human
cov
may
caus
sar
character
fever
myalgia
dri
cough
lymphopenia
sar
patient
develop
atyp
form
pneumonia
among
chang
observ
lung
sar
patient
epitheli
cell
prolifer
desquam
hyalin
membran
format
along
alveolar
wall
immun
cell
infiltr
earli
stage
diseas
increas
fibrosi
multinucl
epitheli
giant
cell
format
later
stage
increas
viral
load
suggest
effect
caus
viral
replic
earli
phase
addit
proinflammatori
cytokin
product
dysregul
may
involv
pathogenesi
sar
one
studi
document
igg
seroconvers
patient
mean
day
time
igg
seroconvers
start
day
correl
fall
viral
load
occur
day
sever
clinic
worsen
explain
uncontrol
viral
replic
occur
lung
damag
phase
therefor
relat
immunemedi
patholog
effect
present
studi
show
autoab
product
also
involv
sarscov
infect
autoab
mainli
igg
start
appear
day
viral
infect
associ
develop
autoimmun
diseas
autoimmun
disord
chronic
diseas
sever
acut
autoimmun
respons
initi
shortli
infect
structur
similar
viral
protein
selfantigen
long
propos
target
immun
crossreact
associ
initi
autoimmun
report
phenomenon
dengu
viru
infect
hypothes
role
immunopathogenesi
dengu
virusinduc
dengu
haemorrhag
fever
dengu
shock
syndrom
find
antiepitheli
cell
autoab
produc
sarscov
infect
anoth
exampl
acut
viral
infectioninduc
autoimmun
virus
characterist
common
lymphotroph
infect
caus
high
fever
lymphopenia
thrombocytopenia
haemorrhag
mild
hepat
cytokin
storm
occur
acut
phase
molecular
mimicri
exist
viru
protein
selfantigen
mous
cov
infect
induc
b
cell
polyclon
activ
gener
autoab
although
autoab
product
sar
patient
caus
cytotox
cell
pneumocyt
whether
autoimmun
respons
may
act
patholog
factor
sar
diseas
need
investig
interestingli
elev
ab
titr
associ
aggrav
respiratori
failur
addit
abmedi
cytotox
releas
chemokin
cytokin
cell
detect
preliminari
result
indic
increas
product
stimul
unpublish
data
recent
report
shown
sarscov
spike
protein
might
elicit
protect
ab
respons
mice
neutral
effect
antisarscov
spike
ab
demonstr
base
result
sequenc
comparison
ncbi
protein
databas
howev
sever
region
sarscov
spike
protein
show
sequenc
homolog
selfantigen
express
human
cell
identifi
sever
candid
protein
recogn
sar
patient
sera
antisarscov
spike
ab
includ
annexin
ii
dehydrogenas
albumin
aldoketo
reductas
transferrin
manuscript
prepar
local
align
javaeuropean
molecular
biolog
open
softwar
suit
jemboss
water
analysi
show
protein
high
degre
homolog
spike
peptid
sequenc
locat
portion
recombin
protein
spike
peptid
block
bind
sar
patient
sera
cell
furthermor
murin
antisera
bind
cell
result
suggest
antisarscov
ab
recogn
crossreact
epitop
human
lung
epitheli
protein
molecular
mimicri
spike
protein
selfantigen
epitop
neutral
ab
domain
crossreact
ab
recogn
epitop
domain
spike
protein
analysi
ab
express
profil
sar
patient
sera
use
studi
indic
igg
start
appear
around
day
antinucleocapsid
n
igg
could
detect
around
day
consist
previou
report
igg
seroconvers
start
day
find
autoab
mainli
igg
appear
day
onset
autoimmun
respons
sarscov
infect
may
import
implic
still
clear
intens
lung
inflamm
develop
even
viral
load
drop
two
week
onset
fever
viru
virusinduc
cytokin
product
might
respons
earli
stage
lung
epitheli
cell
damag
late
autoabmedi
infiltr
cellmedi
inflamm
caus
continu
sustain
alveolar
damag
fibrosi
addit
cell
cell
type
includ
endotheli
cell
hepatocyt
fibroblast
also
bound
autoab
sar
patient
autoab
product
caus
molecular
mimicri
selfantigen
spike
protein
sarscov
might
relat
system
effect
sequela
sar
diseas
furthermor
bind
immun
cell
lung
epitheli
cell
acceler
combin
may
contribut
inflammatori
respons
associ
sar
pathogenesi
hypothesi
need
test
studi
role
autoab
crucial
gain
insight
sar
immunopatholog
mechan
